NCT00894075 is a Phase 2 clinical trial of ENB-0040 in Hypophosphatasia, sponsored by Alexion Pharmaceuticals, Inc..

Who is sponsoring NCT00894075?

NCT00894075 is sponsored by Alexion Pharmaceuticals, Inc..

What drugs are being tested in NCT00894075?

Interventions in NCT00894075: ENB-0040.

What condition does NCT00894075 study?

NCT00894075 studies Hypophosphatasia.

Is NCT00894075 still recruiting?

NCT00894075 is currently withdrawn. Last updated 3 August 2023.

Last reviewed 2023-08-03 · How we verify

NCT00894075

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Single-Center, Case-Control Study of Safety, Efficacy and Pharmacokinetics of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) for Treatment of Hypophosphatasia in Children

Withdrawn Phase 2 Last updated 3 August 2023

What this trial tests

Phase 2 trial testing ENB-0040 in Hypophosphatasia. Withdrawn.

Timeline

1 July 2009

Primary endpoint
1 December 2014

1 December 2014

Quick facts

Lead sponsor	Alexion Pharmaceuticals, Inc.
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 July 2009
Primary completion	1 December 2014
Estimated completion	1 December 2014

Drugs / interventions tested

ENB-0040 — full drug profile →

Conditions studied

Hypophosphatasia — all drugs for Hypophosphatasia →

Sponsor

Alexion Pharmaceuticals, Inc. — full company profile →

Who can join

Adults 5 to 12, any sex, with Hypophosphatasia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Skeletal radiographs using a qualitative Clinical Global Impression of Change (CGI-C) scoring system
Time frame: 6 months

Sponsor's own description

This Clinical Trial is being conducted to study Hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to harden bone. The purpose of this study is to test the safety of the study drug called ENB-0040 and see what effects is has on human juveniles and HPP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hypophosphatasia

Currently open trials in the same condition.

NCT07390240 — The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia · recruiting
NCT06079359 — Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP · Phase 3 · active not recruiting
NCT06079372 — Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa · Phase 3 · active not recruiting
NCT06079281 — Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Trea · Phase 3 · active not recruiting
NCT05234567 — A Prospective Sub-Study of the Global Hypophosphatasia Registry · recruiting

Other Alexion Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT06015750 — Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia · Phase 4 · withdrawn
NCT07352423 — Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants · Phase 1 · recruiting
NCT07221838 — A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab · Phase 4 · recruiting
NCT07413250 — Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis o · active not recruiting
NCT07308574 — Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00894075 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alexion Pharmaceuticals, Inc.
Last refreshed: 3 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00894075.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing